CARsgen Appoints Dr. Hua Jiang as Executive Director
Retrieved on:
Tuesday, August 2, 2022
Jining Medical University, SCI, View, Trust, Development, CAR, Research, Executive, Shanghai Jiao Tong University School of Medicine, National Cancer Institute, Board, Journal of the National Cancer Institute, Multimedia, Shandong University, Pharmacology, Cancer, Medicine, Clinical Cancer Research, Journal, Executive director, Company, Patient, Fudan University, Molecular Therapy, Oregon Economic and Community Development Department, Pharmaceutical industry, Management
SHANGHAI, Aug. 2, 2022 /PRNewswire/ --CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Director of the Company.
Key Points:
- SHANGHAI, Aug. 2, 2022 /PRNewswire/ --CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Director of the Company.
- Dr. Jiang has contributed significantly to the early research, technology platform development, and innovative products development in CARsgen.
- Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, added, "On behalf of the Board, I would like to congratulate Dr. Jiang to be appointed as the Executive Director.
- Dr. Hua Jiang, Executive Director, Vice President of Early Discovery of CARsgen, said, "I am pleased to become a member of the Board and would like to thank the Board for the recognition and trust.